does medi-cal cover semaglutide for weight loss Popular drugs Ozempic and Wegovy would no longer be covered by under a proposal unveiled by Gov. Gavin Newsom Wednesday in an effort to reduce cost overruns in the Semaglutide Weight Loss Treatment in

Description

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness

Blagi neeljeni efekti Ozempica Promena ula ukusa, odreena hrana vie nema isti ukus kao ranije (metalni ili kiseli, opor ukus u ustima) Bol u stomaku Podrigivanje Konstipacija ili dijareja Vrtoglavica Glavobolja Nadutost (gasovi) Umor Probavne smetnje (uznemireni stomak) ili refluks kiseline (goruica) Reakcije organizma na mestu injekcije, kao to su promene boje koe, diskoloracija ili nelagodnost Munina ili povraanje Neznatno poveanje otkucaja srca U veini sluajeva, ovi neeljeni efektisu privremeni